Hester Biosciences Limited — Board Meeting, 09-05-2025: Outcome of Board Meeting

Hester Biosciences has announced a board meeting on the approval of its audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The board has proposed a ₹7 per share (70%) dividend for FY25, pending shareholder approval, and appointed Shah & Shah Associates as Secretarial Auditors for five years. Standalone revenue inched up to ₹286.5 Cr, with PAT rising 17% to ₹31.8 Cr and EPS at ₹37.43. Strong gains came from poultry healthcare (up 16%) and animal healthcare (6%). Consolidated revenue grew 3% to ₹311.1 Cr, with a 36% PAT rise to ₹28.8 Cr, led by reduced losses in subsidiaries. Focus remains on expanding vaccines, feed supplements, and international markets, especially Africa, along with the upcoming Avian Influenza vaccine launch.